Have you heard about the exciting new news in Alzheimer's disease research?
Donanemab, a new disease-modifying drug is currently in the headlines as it appears to slow down memory and thinking decline in people living with early-stage Alzheimer’s disease.
This treatment, rather than just alleviating the symptoms, tackles one of the root causes of Alzheimer's disease. Results from a recent trial have shown a slow down in memory and thinking decline by more than 20%. What's even more promising is that after a year on Donanemab, nearly half of the people had no decline in memory and thinking skills.
The impact of Donanemab doesn't stop there! Those participating in the trial also had a 40% reduction in the decline of their ability to carry out daily activities such as managing finance, driving, and enjoying hobbies.
The drug, developed by Eli Lilly, is an immunotherapy treatment given to patients intravenously. It works by instructing the immune system to identify and remove amyloid proteins, a known contributor to Alzheimer's disease.
Although the journey is ongoing and further trials are required to understand its long-term effects, this drug brings a fresh wave of hope for patients, their families, and caregivers alike.
To read more about this remarkable breakthrough, please click on the link to the article below.
Comentarios